• 한국임상약학회지
• /
• 제30권4호
• /
• pp.250-258
• /
• 2020

Background: Dopamine receptor agonists (DRAs) have been associated with impulse control disorders (ICDs) in Parkinson's disease (PD) in preliminary studies. Whether the association holds true when DRAs are used to treat non-PD, such as restless legs syndrome, prolactinoma, and several mood disorders is uncertain. Objective: The present study aimed to understand the research gaps related to the risk of ICDs associated with pramipexole or ropinirole (PRX/ROP) use as a treatment for specific underlying diseases, excluding Parkinson's disorders. Methods: We conducted a scoping review, systematically searching databases to identify literature on the types, prevalence, and factors associated with ICD in non-PD patients receiving PRX/ROP. All relevant information that helped understand the epidemiology of ICDs among non-PD patients taking PRX/ROP were extracted and analyzed. We also evaluated the potential associations between PRX/ROP and ICDs, utilizing the Naranjo scale or statistical analysis, depending on the type of literature. Results: We included 24 articles (19 case reports or case series and 5 population-based studies) in this scoping review. Evaluating the 19 case reports or case series using Naranjo scores led to the discovery of a possible link between PRX/ROP exposure and ICDs. However, important information to assess causality is frequently missing. Moreover, the population-based studies lack diversity in the study populations and enough study samples to draw conclusive results. Conclusion: Our scoping review suggests that the currently available literature requires more details in future case reports and for well-powered studies in various disease conditions where PRX/ROP is frequently used.

• 수면정신생리
• /
• 제20권1호
• /
• pp.35-40
• /
• 2013

목 적: 임상실제에서 하지불안증후군(restless legs syndrome, RLS) 환자들의 수면다원검사 결과의 특징과 약물치료의 현황을 자연적인 후향성 연구로 조사하는 것이다. 방 법: 임상적으로 RLS의 진단기준을 만족하며 수면다원검사를 시행 받고 치료받은 18세 이상 환자들의 의무기록을 검토하여 분석하였다. 대상자들에 대해 초진시 International Restless Legs Syndrome Study Group(IRLSSG)의 4가지 진단기준과 국제하지불안척도(International Restless Legs Scale, IRLS)를 평가하고 야간수면다원검사와 제안부동검사(suggested immobilization test, SIT)를 시행하였고, 도파민효현제로 한 달간 약물치료 후 IRLS를 재평가하였다. 결 과: 분석에 포함된 총 대상자수는 211명으로 남자가 94명(44.5%), 여자가 117명(55.5%)이었고 평균연령은 46.9세였다. 폐쇄성수면무호흡증이 136명(64.5%), PLMD가 53명(25.1%)에서 동반되어 다른 수면장애를 동반한 환자의 수는 185명(87.7%)이었다. 수면다원검사결과 수면효율은 78.0%, 수면중각성시간(wake after sleep onset)는 86.8분, N3는 3.4%였다. 평균 무호흡저호흡지수(apnea hypopnea index)는 시간당 12.4회, PLMS는 시간당 14.8회, SIT 중 PLMW는 시간당 41.2회였다. 수면중 총 각성지수는 시간당 21.6회였다. 전체 환자 중 ropinirole을 복용한 환자는 149명(70.6%), pramipexole을 복용한 환자수는 47명(22.3%)이었고 ropinirole은 평균 0.9 mg(용량범위 0.125~5 mg), pramipexole은 평균 0.5 mg(용량범위 0.125~4 mg)을 사용하였다. Ropinirole의 용량은 연령과 유의한 양의 상관관계를 보였고(r=0.25, p=0.002), IRLS와도 유의한 양의 상관관계를 보였다(r=0.23, p=0.038). IRLS는 초진시 24.9점에서 1달 뒤 13.4점으로 감소하였다. 결 론: 본 연구의 분석결과 임상적으로 RLS 진단이 가능한 환자 중에 다른 수면장애를 동반하는 경우가 대다수였다. PLMD에 해당되는 사람은 25.1%로 기존 보고보다 적었고 평균 PLMS도 시간당 14.8회로 높지 않았다. 사용하는 도파민효현제의 용량은 한국에서 허가용량으로 승인받은 용량보다 더 높은 경우가 많았다. 향후 이 주제에 대한 전향적이고 통제된 대규모의 연구가 필요하다.

• 한국임상약학회지
• /
• 제30권2호
• /
• pp.81-86
• /
• 2020

Background: The number of patients with dementia continues to increase as the age of aging continues to grow. Psychiatric symptoms caused by senile dementia are controlled using antipsychotics. However, these antipsychotics can lead to Parkinson's disease, and abuse of dopamine derivatives such as levodopa among Parkinsonian drugs can lead to psychosis. Therefore, we evaluated the patterns of prescribed antipsychotics and antiparkinsonian drugs in patients with senile dementia. Methods: We used data from the sample of elderly patients from the Health Insurance Review and Assessment Service (HIRA-APS-2016). We analyzed the patterns of prescribing antipsychotics and antiparkinsonian drugs including prescribed daily dosage, period of prescription, and number of patients with both antipsychotics and antiparkinsonian drugs for senile dementia. Results: Among the 159,391 patients with dementia included in this analysis, 4,963 patients (3.1%) and 16,499 patients (10.4%) were prescribed typical and atypical antipsychotic drugs, respectively. The most frequently prescribed typical antipsychotic was haloperidol (4,351 patients with dementia), whereas the atypical agent was quetiapine (12,719 patients). The most frequently prescribed antiparkinsonian drugs were in the order of levodopa/carbidopa, benztropine, and ropinirole. In addition, 1,103 and 3,508 patients prescribed typical and atypical antipsychotics, respectively, were co-prescribed antiparkinsonian drugs. Conclusions: Atypical antipsychotics were the preferred prescription in patients with senile dementia. The prescription dose was relatively low; however, the average treatment duration was mostly long-term. Selection of antipsychotics and/or antiparkinsonian drugs should be made carefully in senile dementia and the causal relationship of adverse drug reactions needs further study.